Terapias Avanzadas para Tumores Sólidos Pediátricos
University of California, San Francisco
San Francisco, Estados UnidosPublicaciones en colaboración con investigadores/as de University of California, San Francisco (12)
2024
-
A road map for the treatment of pediatric diffuse midline glioma
Cancer Cell
-
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models
Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525
2023
-
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393
-
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378
-
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8
-
Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology
Neoplasia (United States), Vol. 42
2016
-
Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome
Nature Communications, Vol. 7
-
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis
Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477
2015
-
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types
Journal of the National Cancer Institute, Vol. 107, Núm. 12
-
Characterization of large structural genetic mosaicism in human autosomes
American Journal of Human Genetics, Vol. 96, Núm. 3, pp. 487-497
2014
-
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633
2006
-
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan
Clinical Cancer Research, Vol. 12, Núm. 2, pp. 556-562